The reliability and validity of a modified total neuropathy score-reduced and neuropathic pain severity items when used to measure chemotherapy-induced peripheral neuropathy in patients receiving taxanes and platinums

Cancer Nursing

Volumn 33, Issue 3, 2010, Pages 173-183

  Smith, Ellen M Lavoie ^a   Cohen, Jeffrey A ^b   Pett, Marjorie A ^c   Beck, Susan L ^c  

^a UNIVERSITY OF MICHIGAN SCHOOL OF NURSING   (United States)

^b DARTMOUTH MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF UTAH   (United States)

Author keywords

Chemotherapy; Neuropathic Pain Score; Peripheral neuropathy; Platinums; Reliability; Taxanes; Total neuropathy score; Validity

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; OXALIPLATIN; PACLITAXEL; PLATINUM; TAXANE DERIVATIVE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; FEMALE; HUMAN; INTERNAL CONSISTENCY; INTERRATER RELIABILITY; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NEOPLASM; NEUROPATHIC PAIN; PAIN ASSESSMENT; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RELIABILITY; SCORING SYSTEM; VALIDITY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; FACTOR ANALYSIS, STATISTICAL; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROLOGIC EXAMINATION; NEW HAMPSHIRE; NEW JERSEY; NURSE PRACTITIONERS; NURSING ASSESSMENT; NURSING EVALUATION RESEARCH; OBSERVER VARIATION; ONCOLOGIC NURSING; PAIN MEASUREMENT; PERIPHERAL NERVOUS SYSTEM DISEASES; PLATINUM COMPOUNDS; PSYCHOMETRICS; QUESTIONNAIRES; SEVERITY OF ILLNESS INDEX; SINGLE-BLIND METHOD; STATISTICS, NONPARAMETRIC; TAXOIDS;

EID: 77951767251     PISSN: 0162220X     EISSN: None     Source Type: Journal    
DOI: 10.1097/NCC.0b013e3181c989a3     Document Type: Article

References (24)

1. Smith EL, Beck SL, Cohen J. The total neuropathy score (TNS): a tool for measuring chemotherapy-induced peripheral neuropathy. Oncol Nurs Forum. 2008;35(1):96-102.
2. Anonymous. Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. The elderly lung cancer vinorelbine Italian study group. J Natl Cancer Inst. 1999; 91(1):66-72.
3. Ostchega Y, Donohue M, Fox N. High-dose cisplatin-related peripheral neuropathy. Cancer Nurs. 1988;11(1):23-32.
4. Wampler MA, Miaskowski C, Hamel K, Byl N, Rugo H, Topp LS. The modified total neuropathy score: a clinically feasible and valid measure of taxane-induced peripheral neuropathy in women with breast cancer. Support Oncol. 2006;4(8):W9-W16.
5. England JD, Gronseth GS, Franklin G, et al. Distal symmetric polyneuropathy: a definition for clinical research: report of the American Academy of Neurology, the American Association of Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation. Neurology. 2005;64(2):199-207.
6. Galer B. Painful polyneuropathy. Neurol Clin. 1998;16(4):791-812.
7. Marrs J, Newton S. Updating your peripheral neuropathy ''know-how''. Clin J Oncol Nurs. 2003;7(3):299-303.
8. Cavaletti G, Bogliun G, Marzorati L, et al. Grading of chemotherapyinduced peripheral neurotoxicity using the total neuropathy scale. Neurology. 2003;61(9):1297-1300.
9. Cavaletti G, Jann S, Pace A, et al. Multi-center assessment of the total neuropathy score for chemotherapy-induced peripheral neurotoxicity. J Peripher Nerv Syst. 2006;11(2):135-141.
10. Chaudhry V, Rowinsky EK, Sartorius SE, Donehower RC, Cornblath DR. Peripheral neuropathy from taxol and cisplatin combination chemotherapy: clinical and electrophysiological studies. Ann Neurol. 1994; 35(3):304-311.
11. Chaudhry V, Eisenberger MA, Sinibaldi VJ, Sheikh K, Griffin JW, Cornblath DR. A prospective study of suramin-induced peripheral neuropathy. Brain. 1996;119(Pt 6):2039-2052.
12. Chaudhry V, Cornblath DR, Corse A, Freimer M, Simmons-O'Brien E, Vogelsang G. Thalidomide-induced neuropathy. Neurology. 2002; 59(12):1872-1875.
13. Wright JG, Feinstein AR. A comparative contrast of clinimetric and psychometric methods for constructing indexes and rating scales. J Clin Epidemiol. 1992;45(11):1201-1218.
14. Galer BS, Jensen MP. Development and preliminary validation of a pain measure specific to neuropathic pain: the Neuropathic Pain Scale. Neurology. 1997;48(2):332-338.
15. Jensen MP, Gammaitoni AR, Olaleye DO, Oleka N, Nalamachu SR, Galer BS. The Pain Quality Assessment Scale: assessment of pain quality in carpal tunnel syndrome. J Pain. 2006;7(11):823-832.
16. Jensen MP, Dworkin RH, Gammaitoni AR, Olaleye DO, Oleka N, Galer BS. Assessment of pain quality in chronic neuropathic and nociceptive pain clinical trials with the Neuropathic Pain Scale. J Pain. 2005; 6(2):98-106.
17. Jensen MP, Friedman M, Bonzo D, Richards P. The validity of the Neuropathic Pain Scale for assessing diabetic neuropathic pain in a clinical trial. Clin J Pain. 2006;22(1):97-103.
18. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977;33(1):159-174.
19. Bruera E, Belzile M, Pituskin E, et al. Randomized, double-blind, crossover trial comparing safety and efficacy of oral controlled-release oxycodone with controlled-release morphine in patients with cancer pain. J Clin Oncol. 1998;16(10):3222-3229.
20. Kaiser HF. An index of factorial simplicity. Psychometrika. 1974;39: 32-36.
21. Pett MA, Lackey NR, Sullivan JL. Making Sense of Factor Analysis: The Use of Factor Analysis for Instrument Development in Health Care Research. Thousand Oaks, CA: Sage Publications; 2003.
22. Ferketich S. Focus on psychometrics: aspects of item analysis. Res Nurs Health. 1991;14(2):165-168.
23. Cavaletti G, Bogliun G, Marzorati L, et al. Early predictors of peripheral neurotoxicity in cisplatin and paclitaxel combination chemotherapy. Ann Oncol. 2004;15(9):1439-1442.
24. Fayers PM. Quality-of-life measurement in clinical trialsVthe impact of causal variables. J Biopharm Stat. 2004;14(1):155-176.